NLM Digital Collections

Search

Start Over Subjects Drug Costs ✖Remove constraint Subjects: Drug Costs Copyright Public domain ✖Remove constraint Copyright: Public domain

2. Medicare Part B drug payments: impact of price substitutions based on 2014 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2017
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Medicare Part B -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

3. Medicare Part B drug payments: impact of price substitutions based on 2015 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2017
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Medicare -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

4. Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2017
Subject(s):
Drug Costs
Insurance, Pharmaceutical Services -- economics
Medicare Part B -- economics
Prospective Payment System
Abatacept -- economics
Certolizumab Pegol -- economics
Cost Savings
Injections -- economics
Self Care -- economics
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)
Healthcare common procedure coding system

5. Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, December 2017
Subject(s):
Drug Costs
Drug Industry -- economics
Medicaid -- economics
Pharmaceutical Preparations -- classification
Pharmaceutical Preparations -- economics
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

6. Medicare Part B drug payments: impact of price substitutions based on 2016 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2018
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Medicare Part B -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

9. Prices for and spending on specialty drugs in Medicare Part D and Medicaid: an in-depth analysis

Author(s):
Anderson-Cook, Anna, author
Maeda, Jared, author
Nelson, Lyle, author
Publication:
[Washington, DC] : Congressional Budget Office, March 2019
Subject(s):
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs
Economics, Pharmaceutical -- trends
Forecasting
Medicaid -- trends
Medicare Part D -- trends
Orphan Drug Production -- economics
Humans
United States

10. Prices for and spending on specialty drugs in Medicare Part D and Medicaid

Publication:
[Washington, DC] : Congressional Budget Office, March 2019
Subject(s):
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs
Economics, Pharmaceutical -- trends
Forecasting
Medicaid -- trends
Medicare Part D -- trends
Orphan Drug Production -- economics
Humans
United States

11. Medicare and mental health: the fundamentals

Publication:
Washington, D.C. : George Washington University, [2006]
Subject(s):
Insurance Coverage
Medicare -- economics
Mental Disorders -- economics
Mental Health -- statistics & numerical data
Community Mental Health Services -- economics
Disabled Persons
Disease Management
Drug Costs
Health Expenditures
Hospitalization -- economics
Insurance, Pharmaceutical Services
Medicaid -- economics
Medicare -- statistics & numerical data
Mental Disorders -- epidemiology
Mental Disorders -- therapy
Mental Health Services -- economics
Prevalence
Psychotropic Drugs -- economics
Humans
United States
Medicare Payment Advisory Commission (U.S.)

13. Drug industry: profits, research and development spending, and merger and acquisition deals : report to Congressional requesters

Publication:
Washington, DC : United States Government Accountability Office, November 2017
Subject(s):
Drug Costs
Drug Industry -- economics
Economics, Pharmaceutical -- trends
Pharmaceutical Research -- economics
Pharmaceutical Research -- trends
Antitrust Laws
Biological Products -- economics
Drug Approval -- economics
Drug Development -- economics
Drug Development -- trends
Economic Competition
Forecasting
Orphan Drug Production -- economics
Taxes
Humans
United States
National Institutes of Health (U.S.)

14. Medicare Part B: Medicare represented at least half of the market for 22 of the 84 most expensive drugs in 2015 : report to Congressional requesters

Publication:
Washington, DC : United States Government Accountability Office, December 2017
Subject(s):
Drug Costs
Health Care Sector
Health Expenditures
Medicare Part B -- economics
Insurance, Health, Reimbursement
Medicare Part B -- statistics & numerical data
Humans
United States

15. Report on the affordability of insulin

Author(s):
Finegold, Kenneth, 1957- author
Sayed, Bisma A., author
Publication:
Washington, D.C. : U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, December 16, 2022
Subject(s):
Costs and Cost Analysis
Drug Costs
Health Expenditures
Insulin -- economics
Diabetes Mellitus -- drug therapy
Diabetes Mellitus -- economics
Medication Adherence
United States

19. Drug discount program: status of agency efforts to improve 340B program oversight : testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate

Publication:
Washington, DC : United States Government Accountability Office, May 15, 2018
Subject(s):
Drug Costs
Economics, Pharmaceutical
Government Regulation
Medicaid -- economics
United States
United States. Health Resources and Services Administration.

21. Drug discount program: improvements needed in federal oversight of compliance at 340B contract pharmacies : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives

Publication:
Washington, DC : United States Government Accountability Office, July 11, 2018
Subject(s):
Drug Costs
Economics, Pharmaceutical
Pharmacies -- economics
Contract Services
Government Regulation
United States
United States. Health Resources and Services Administration.

22. Medicare Part B drug payments: impact of price substitutions based on 2017 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2019
Subject(s):
Cost Control
Cost Savings
Drug Costs
Insurance, Health, Reimbursement
Medicare Part B -- economics
Reimbursement Mechanisms
Economics, Pharmaceutical
Humans
United States
Centers for Medicare & Medicaid Services (U.S.)

28. Medicare Part D: CMS should monitor effects of rebates on plan formularies and beneficiary spending : report to congressional requesters

Publication:
Washington, DC : United States Government Accountability Office, September 2023
Subject(s):
Drug Costs
Government Regulation
Legislation, Medical
Medicare Part D -- economics
Medicare Part D -- organization & administration
Prescription Fees
United States
Centers for Medicare & Medicaid Services (U.S.)

Refine by:

more »

more »

more »

Current results range from 1960 to 2023